BioSpace News Archive

This transaction increases BioIVT’s global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studies showing the impact that cell-based and adjuvanted influenza vaccines can have in reducing the burden of seasonal influenza on hospitals and health systems.

Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors.

BlueSphere Bio today announced the presentation of preclinical data supporting the ability of its TCXpress™ and iTCXpress™ platforms to rapidly and efficiently identify novel TCR candidates at the 7th annual CAR-TCR Summit from September 19 - 22, 2022.

Shanghai Fosun Pharma (Group) Co., Ltd. today announced that the 20 ml, Sodium Phenylacetate and Sodium Benzoate (SPSB) liquid product, which is under an exclusive partnership between Fosun Pharma USA Inc. (“Fosun Pharma USA”), the US-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma"; stock code: 600196. SH, 02196. HK) and MAIA Pharmaceuticals, Inc. (MAIA), a Princeton, NJ based specialty pharmaceutical company, has been recently launched.

Actylis, a leading global manufacturer and sourcing expert of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, made its debut.

The global dried blood spot collection cards market size was valued at USD 350.6 million in 2021 and it is predicted to hit around USD 517.83 million by 2030 with a CAGR of 4.43% from 2022 to 2030.

ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.

Creative Enzymes, a professional enzyme provider located in New York, USA, is always hammering away at research and trials in order to provide customers with enzyme services and products with its greatest effort.

Prodeon Medical, Inc. today announced the randomization of the first patient in the EXPANDER-2 pivotal clinical trial (NCT: 05400980, A Multi-Center, Randomized, Blinded, Controlled Study to Evaluate the Safety and Efficacy of the Urocross™ Expander System and Retrieval Sheath).